Interleukin-6-174G/C polymorphism in breast cancer and uterine leiomyoma patients: A population-based case control study

Experimental Oncology

Volumn 29, Issue 4, 2007, Pages 295-298

  Litovkin, K V ^a   Domenyuk, V P ^a   Bubnov, V V ^a   Zaporozhan, V N ^a  

^a ODESSA NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Breast cancer; IL 6; Polymorphism; Uterine leiomyoma

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PROTEIN POLYMORPHISM; UTERUS MYOMA;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; LEIOMYOMA; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS; UKRAINE; UTERINE NEOPLASMS;

EID: 39049148410     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Conze D, Weiss L, Regen PS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61: 8851-8.
2. Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-37.
3. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16: 249-84.
4. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6.
5. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003; 83: 222-6.
6. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19: 1427-32.
7. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237-9.
8. Ray A, LaForge KS, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 1990; 10: 5736-46.
9. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
10. Rivera-Chavez FA, Peters-Hybki DL, Barner RC, et al. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 2003; 20: 218-23.
11. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G > C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22: 2066-71.
12. Du Y, Berthier-Schaad Y, Fallin MD, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006; 17: 863-70.
13. Landi S, Moreno V, Gioia-Patricola L, et al. Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003; 63: 3560-6.
14. Iacopetta B, Grieu F, Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Brit J Cancer 2004; 90: 419-22.
15. DeMichele A, Martin AM, Mick R, et al. Interleukin-6 -174G/C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63: 8051-6.
16. Berger FG. The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Br Cancer Res Treat 2004; 88: 281-5.
17. Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006; 107: 917-21.
18. Hsieh YY, Chang CC, Tsai CH, et al. Interleukin (IL)-12 receptor beta1 codon 378 G homozygote and allele, but not IL-1 (beta-511 promoter, 3953 exon 5, receptor antagonist), IL-2 114, IL-4-590 intron 3, IL-8 3′-UTR 2767, and IL-18 105, are associated with higher susceptibility to leiomyoma. Fertil Steril 2007; 87: 886-95.
19. Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin North Am 2006; 33: 41-58.
20. Hefler LA, Grimm C, Lantzsch T, et al. Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in Caucasian women. Clin Cancer Res 2005; 11: 5718-21.
21. Gonzalez-Zuloeta Ladd AM, Arias Vasquez A, et al. Interleukin 6 G-174 C polymorphism and breast cancer risk. Eur J Epidemiol 2006; 21: 373-6.
22. Smith KC, Bateman AC, Fussell HM, et al. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 2004; 31: 167-73.
23. Meenagh A, Williams F, Ross OA, et al. Frequency of cytokine polymorphisms in populations from Western Europe, Africa, Asia, the Middle East and South America. Hum Immunol 2002; 63: 1055-61.
24. Trajkov D, Arsov T, Petlichkovski A, et al. Cytokine gene polymorphisms in population of ethnic Macedonians. Croat Med J 2005; 46: 685-92.
25. Poli F, Nocco A, Berra S, et al. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet 2002; 29: 237-40.
26. Rauramaa R, Vaisanen SB, Luong LA, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2657-62.
27. Balasubramanian SP, Azmy IAF, Higham SE, et al. Interleukin gene polymorphisms and breast cancer a case control study and systematic literature review. BMC Cancer 2006; 6: ???
28. Vollenhoven BJ, Lawrence AS, Healy DL. Uterine fibroids: a clinical review. Br J Obstet Gynaecol 1990; 97: 285-98.
29. Kawaguchi K, Fujj S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989; 160: 637-41.
30. Skubitz KM, Skubitz APN. Differential gene expression in uterine leiomyoma. Lab Clin Med 2003; 141: 297-308.
31. Diakowska D, Markocka-Maczka K, Grabowski K, et al. Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp Oncol 2006; 28: 319-22.